Expertise in
6
conditions

Valerie Boige

Gustave Roussy
Villejuif, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Gustave Roussy
Villejuif, FR 

Overview

Valerie Boige practices practicing medicine in Villejuif, France.

Ms. Boige is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Hepatectomy, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 156 peer reviewed articles and participating in 11 clinical trials.

Gender

Female

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin intravenous, 5 Fu, Folinic Acid, Oxaliplatin intra-arterial, Panitumumab, Bevacizumab
Study Phase: Phase 3
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2025
Intervention Type: Drug
Study Phase: Phase 3
Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 3
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Drug: Nivolumab+Ipilimumab
Study Phase: Phase 2
Diffusion-Weighted Magnetic Resonance Imaging Assessment of Liver Metastasis to Improve Surgical Planning
Diffusion-Weighted Magnetic Resonance Imaging Assessment of Liver Metastasis to Improve Surgical Planning
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Procedure
A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma
A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma
Enrollment Status: Completed
Publish Date: October 13, 2023
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

156 Total Publications

Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients.
Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

Frequently Asked Questions about Valerie Boige

Is Valerie Boige a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Valerie Boige is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Valerie Boige participate in research or clinical trials?

Yes. Valerie Boige has published 156 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Valerie Boige's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Boige's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile